Table of Contents Table of Contents
Previous Page  834 860 Next Page
Information
Show Menu
Previous Page 834 860 Next Page
Page Background

Study concept and design:

Heck, Winter.

Acquisition of data:

Thoene, Secci, Winter, Seitz, Nawroth, Tauber,

Thalgott, Schmid, Heck.

Analysis and interpretation of data:

Heck, Winter, Bietenbeck, Seitz.

Drafting of the manuscript:

Heck, Seitz, Winter.

Critical revision of the manuscript for important intellectual content:

Thoene, Bietenbeck, Tauber, Nawroth, Retz, Gschwend, Ruland.

Statistical analysis:

Winter, Heck.

Obtaining funding:

None.

Administrative, technical, or material support:

Ruland.

Supervision:

Heck, Winter.

Other:

None.

Financial disclosures:

Matthias M. Heck certi

fi

es that all con

fl

icts of

interest, including speci

fi

c

fi

nancial interests and relationships and

af

fi

liations relevant to the subject matter or materials discussed in the

manuscript (eg, employment/af

fi

liation, grants or funding, consultan-

cies, honoraria, stock ownership or options, expert testimony, royalties,

or patents

fi

led, received, or pending), are the following: None.

Funding/Support and role of the sponsor:

None.

Appendix A. Supplementary data

Supplementary data associated with this article can be

found, in the online version, at

http://dx.doi.org/10.1016/ j.eururo.2017.07.024 .

References

[1]

Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, et al. Cancer inci- dence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 2013;49:1374 403

.

[2]

Sridhar SS, Freedland SJ, Gleave ME, et al. Castration-resistant prostate cancer: from new pathophysiology to new treatment. Eur Urol 2014;65:289 99

.

[3]

Coutinho I, Day TK, Tilley WD, et al. Androgen receptor signaling in castration-resistant prostate cancer: a lesson in persistence. Endocr Relat Cancer 2016;23:T179 97

.

[4]

de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011;364: 1995 2005

.

[5]

Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012;367: 1187 97

.

[6]

Ryan CJ, Smith MR, Fizazi K, et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA- 302): fi nal overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 2015;16:152 60

.

[7]

Beer TM, Armstrong AJ, Rathkopf DE, et al. Enzalutamide in meta- static prostate cancer before chemotherapy. N Engl J Med 2014;371:424 33

.

[8]

Antonarakis ES, Lu C, Wang H, et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med 2014;371:1028 38

.

[9]

Maughan BL, Antonarakis ES. Androgen pathway resistance in prostate cancer and therapeutic implications. Expert Opin Phar- macother 2015;16:1521 37

.

[10]

Watson PA, Arora VK, Sawyers CL. Emerging mechanisms of resis- tance to androgen receptor inhibitors in prostate cancer. Nat Rev Cancer 2015;15:701 11.

[11]

Steinestel J, Luedeke M, Arndt A, et al. Detecting predictive andro- gen receptor modi fi cations in circulating prostate cancer cells. Oncotarget 2015;6:12035 47

.

[12]

Scher HI, Graf RP, Schreiber NA, et al. Nuclear-speci fi c AR-V7 protein localization is necessary to guide treatment selection in metastatic castration-resistant prostate cancer. Eur Urol 2016;71:874 82.

[13]

Liu X, Ledet E, Li D, et al. A whole blood assay for AR-V7 and AR v567es in prostate cancer patients. J Urol 2016;196:1758 63

.

[14]

Todenhöfer T, Azad A, Stewart C, et al. AR-V7 transcripts in whole blood RNA of patients with metastatic castration resistant prostate cancer correlate with response to abiraterone acetate. J Urol 2016;197:135 42.

[15]

Qu F, Xie W, Nakabayashi M, et al. Association of AR-V7 and prostate-speci fi c antigen RNA levels in blood with ef fi cacy of abir- aterone acetate and enzalutamide treatment in men with prostate cancer. Clin Cancer Res 2017;23:726 34.

[16]

Del Re M, Biasco E, Crucitta S, et al. The detection of androgen receptor splice variant 7 in plasma-derived exosomal RNA strongly predicts resistance to hormonal therapy in metastatic prostate cancer patients. Eur Urol 2017;71:680 7.

[17]

Usher JL, Athreya K, Ishiba T, et al. Detection of AR-V7 using cell-free RNA (cfRNA) in prostate cancer. J Clin Oncol 2016;34(15 Suppl): 16613

.

[18]

Kölbl AC, Jeschke U, Andergassen U. The signi fi cance of epithelial- to-mesenchymal transition for circulating tumor cells. Int J Mol Sci 2016;17:1308.

[19]

Scher HI, Halabi S, Tannock I, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working *Group. J Clin Oncol 2008;26:1148 59.

[20]

Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205 16.

[21]

McShane LM, Altman DG, Sauerbrei W, et al. REporting recommen- dations for tumor MARKer prognostic studies (REMARK). Breast Cancer Res Treat 2006;100:229 35.

[22]

Huggett JF, Foy CA, Benes V, et al. The Digital MIQE guidelines: minimum information for publication of quantitative digital PCR experiments. Clin Chem 2013;59:892 902.

[23]

Takeuchi T, Okuno Y, Hattori-Kato M, et al. Detection of AR-V7 mRNA in whole blood may not predict the effectiveness of novel endocrine drugs for castration-resistant prostate cancer. Res Rep Urol 2016;8:21 5

.

[24]

Antonarakis ES, Lu C, Luber B, et al. Androgen receptor splice variant 7 and ef fi cacy of taxane chemotherapy in patients with metastatic castration-resistant prostate cancer. JAMA Oncol 2015;1:582 91.

[25]

Nakazawa M, Lu C, Chen Y, et al. Serial blood-based analysis of AR- V7 in men with advanced prostate cancer. Ann Oncol 2015;26: 1859 65

.

[26]

Onstenk W, Sieuwerts AM, Kraan J, et al. Ef fi cacy of cabazitaxel in castration-resistant prostate cancer is independent of the presence of AR-V7 in circulating tumor cells. Eur Urol 2015;68: 939 45

.

[27]

Bernemann C, Schnoeller TJ, Luedeke M, et al. Expression of AR-V7 in circulating tumour cells does not preclude response to next generation androgen deprivation therapy in patients with castra- tion resistant prostate cancer. Eur Urol 2016;71:1 3.

[28]

Whale AS, Devonshire AS, Karlin-Neumann G, et al. International interlaboratory digital PCR study demonstrating high reproducibil- ity for the measurement of a rare sequence variant. Anal Chem 2017;89:1724 33

.

E U R O P E A N U R O L O GY 7 2 ( 2 0 17 ) 8 2 8

8 3 4

834